Nalbuphine ER · Haduvio
Small molecule
Evidence outlook · registrational
Chronic Cough in Idiopathic Pulmonary Fibrosis: registrational readout pending
Its supporting mid-stage studies have completed. ClinicalTrials.gov estimates the registrational readout at 2028-06; company guidance (Trevi Therapeutics, Inc., stated 2026-11-09): topline data expected first half of 2028. The sponsor reported topline results of a Phase 2 study on 2025-06-02 (Phase 2b CORAL of Haduvio (nalbuphine ER) in IPF chronic cough met its primary endpoint); that is not the registrational readout.
Also in development:Prurigo Nodularis · Phase 2/3
Company guidance: topline data expected second half of 2027 (NCT07868419; Trevi Therapeutics, Inc., 9 Nov 2026). “The 12-week fixed-dose OCEAN-2 trial , was initiated in the third quarter of 2026, and topline results are expected in the second half of 2027.” Source ↗
Company guidance: topline data expected first half of 2028 (NCT07671911; Trevi Therapeutics, Inc., 9 Nov 2026). “The 52-week fixed-dose OCEAN-1 trial was initiated in the second quarter of 2026, and topline results are expected in the first half of 2028.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
OCEAN-1 NCT07671911 · Idiopathic Pulmonary Fibrosis Registry: NCT07671911 | 3 | Relative Change from Baseline in 24-hour Cough Frequency at Week 26 (Baseline, Week 26) 2028-06 | In progress: results expected 1 Jun 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Prurigo Nodularis: Phase 2/3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Nalbuphine ER (Haduvio): this drug | Phase 2/3 | Small molecule | Kappa-opioid receptor (agonist); mu-opioid receptor (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Dupilumab (Dupixent) | Approved | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Nemolizumab (Nemluvio) | Approved | Monoclonal antibody | IL-31 receptor A | Reliable signal | No reviewed efficacy summary in this indication | |
| Ruxolitinib (Opzelura) | Phase 3 | Small molecule | JAK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Stapokibart | Phase 3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| AK139 | Phase 2 | Multispecific antibody | IL-4 receptor alpha / ST2 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Haduvio (Nalbuphine ER) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
November 2026 (1)
What to watch
2027 (2)
August 2027 (1)
Company guidance: topline data expected second half of 2027 (Trevi Therapeutics, Inc., 9 Nov 2026). “The 12-week fixed-dose OCEAN-2 trial , was initiated in the third quarter of 2026, and topline results are expected in the second half of 2027.” Source ↗
What to watch
September 2027 (1)
What to watch
2028 (1)
June 2028 (1)
Company guidance: topline data expected first half of 2028 (Trevi Therapeutics, Inc., 9 Nov 2026). “The 52-week fixed-dose OCEAN-1 trial was initiated in the second quarter of 2026, and topline results are expected in the first half of 2028.” Source ↗
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent